Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates

Group 1 - Regenxbio reported quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41 per share, compared to a loss of $1.38 per share a year ago, representing an earnings surprise of -70.73% [1] - The company posted revenues of $89.01 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 19.07%, compared to year-ago revenues of $15.62 million [2] - Over the last four quarters, Regenxbio has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Group 2 - The stock's immediate price movement will depend on management's commentary on the earnings call and the sustainability of earnings expectations [3][4] - Regenxbio shares have lost about 2.7% since the beginning of the year, while the S&P 500 has declined by 3.8% [3] - The current consensus EPS estimate for the coming quarter is -$1.21 on $21.98 million in revenues, and -$0.88 on $295.17 million in revenues for the current fiscal year [7] Group 3 - The Medical - Biomedical and Genetics industry, to which Regenxbio belongs, is currently in the top 34% of the Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5][6]